Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review.

Abstract

BackgroundUnderstanding the cost of delivering breast cancer (BC) care in low‐ and middle‐income countries (LMICs) is critical to guide effective care delivery strategies. This scoping review summarizes the scope of literature on the costs of BC care in LMICs and characterizes the methodological approaches of these economic evaluations.Materials and MethodsA systematic literature search was performed in five databases and gray literature up to March 2020. Studies were screened to identify original articles that included a cost outcome for BC diagnosis or treatment in an LMIC. Two independent reviewers assessed articles for eligibility. Data related to study characteristics and methodology were extracted. Study quality was assessed using the Drummond et al. checklist.ResultsNinety‐one articles across 38 countries were included. The majority (73%) of studies were published between 2013 and 2020. Low‐income countries (2%) and countries in Sub‐Saharan Africa (9%) were grossly underrepresented. The majority of studies (60%) used a health care system perspective. Time horizon was not reported in 30 studies (33%). Of the 33 studies that estimated the cost of multiple steps in the BC care pathway, the majority (73%) were of high quality, but studies varied in their inclusion of nonmedical direct and indirect costs.ConclusionThere has been substantial growth in the number of BC economic evaluations in LMICs in the past decade, but there remain limited data from low‐income countries, especially those in Sub‐Saharan Africa. BC economic evaluations should be prioritized in these countries. Use of existing frameworks for economic evaluations may help achieve comparable, transparent costing analyses.Implications for PracticeThere has been substantial growth in the number of breast cancer economic evaluations in low‐ and middle‐income countries (LMICs) in the past decade, but there remain limited data from low‐income countries. Breast cancer economic evaluations should be prioritized in low‐income countries and in Sub‐Saharan Africa. Researchers should strive to use and report a costing perspective and time horizon that captures all costs relevant to the study objective, including those such as direct nonmedical and indirect costs. Use of existing frameworks for economic evaluations in LMICs may help achieve comparable, transparent costing analyses in order to guide breast cancer control strategies.